Literature DB >> 16627990

Human tumor mutants in the p110alpha subunit of PI3K.

Zhenning Liu1, Thomas M Roberts.   

Abstract

The PI3K-Akt pathway is frequently upregulated in human tumors. Recently, somatic mutations of PIK3CA, encoding p110alpha catalytic subunit of Class IA PI3Ks, have been found in various cancers. The two most common types of p110alpha mutants, those in the helical and kinase domains, have been shown to be very potent in Akt activation and oncogenic transformation by several groups. Notably these common mutations may not enhance recruitment of p110alpha to the plasma membrane where its substrates are located. We have investigated the effect of membrane localization on common PIK3CA tumor mutants via myristoylation. In addition we have studied a third class of less frequent mutants in the p85-binding domain, in an attempt to gain insight into p85's inhibitory effect on p110alpha. This article briefly reviews and extends the literature on mutant forms of p110alpha.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627990     DOI: 10.4161/cc.5.7.2605

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Rare cancer-specific mutations in PIK3CA show gain of function.

Authors:  Marco Gymnopoulos; Marc-André Elsliger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-21       Impact factor: 11.205

Review 2.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

3.  p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.

Authors:  Aditi Chaudhari; Daniel Krumlinde; Annika Lundqvist; Levent M Akyürek; Sashidhar Bandaru; Kristina Skålén; Marcus Ståhlman; Jan Borén; Yvonne Wettergren; Katarina Ejeskär; Victoria Rotter Sopasakis
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

4.  Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Authors:  Stefan S De Buck; Annamaria Jakab; Markus Boehm; Douglas Bootle; Dejan Juric; Cornelia Quadt; Timothy K Goggin
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.

Authors:  Xun Li; Quanbao Zhang; Wenting He; Wenbo Meng; Jun Yan; Lei Zhang; Xiaoliang Zhu; Tao Liu; Yumin Li; Zhongtian Bai
Journal:  Pathol Oncol Res       Date:  2011-06-12       Impact factor: 3.201

Review 6.  Phosphatidylinositol 3-kinase: the oncoprotein.

Authors:  Peter K Vogt; Jonathan R Hart; Marco Gymnopoulos; Hao Jiang; Sohye Kang; Andreas G Bader; Li Zhao; Adam Denley
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 7.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 8.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

9.  Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Authors:  Shidong Jia; Zhenning Liu; Sen Zhang; Pixu Liu; Lei Zhang; Sang Hyun Lee; Jing Zhang; Sabina Signoretti; Massimo Loda; Thomas M Roberts; Jean J Zhao
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.